ライフサイエンスコーパス: noninferiority trial

1 late loss at 9-month angiographic follow-up (noninferiority trial).

2 dy, a prospective, randomized, single-blind, noninferiority trial.

3 egimen versus rituximab may require a global noninferiority trial.

4 andomized, multicenter, single-blind, 2-arm, noninferiority trial.

5 ional, multicenter, double-blind, randomized noninferiority trial.

6 ARLY-SIMPLIFIED is a randomized, open-label, noninferiority trial.

7 ducted a prospective, open-label, randomized noninferiority trial.

8 [1500 kcal (6000 kJ); n = 60] in this 12-mo noninferiority trial.

9 re enrolled in HOME2, a 12-month, randomized noninferiority trial.

10 s was a randomized, multicenter, open-label, noninferiority trial.

11 ndomized, multicenter, open-label, phase III noninferiority trial.

12 gh Risk Trial was a multicenter, randomized, noninferiority trial.

13 veness (SALOME) was a phase 3, double-blind, noninferiority trial.

14 eek, randomized, double-blind, double-dummy, noninferiority trial.

15 154 patients, 173 lesions) in a multicenter, noninferiority trial.

16 be aided by quantitative approaches used in noninferiority trials.

17 ity trials may produce misleading results in noninferiority trials.

18 endpoints could improve the design of future noninferiority trials.

19 on, and applicability of results specific to noninferiority trials.

20 erior to that of standard therapy are called noninferiority trials.

21 uated in the context of 8 recently published noninferiority trials.

22 me data from a carefully specified subset of noninferiority trials.

23 ssed for the risk of bias in equivalence and noninferiority trials.

24 masked, active comparator-controlled phase 3 noninferiority trials.

25 the methodology and reporting of antibiotic noninferiority trials.

26 double-masked, active comparator-controlled, noninferiority trials.

27 ostate cancer deaths in both superiority and noninferiority trials.

28 ducted a randomized, controlled, open-label, noninferiority trial (10% margin) to compared immunogeni

29 In this randomized, open label noninferiority trial, 190 patients admitted with ACS wit

30 In this open-label multicenter phase III noninferiority trial, 4,806 patients underwent SN biopsy

31 -randomized, investigator-masked, crossover, noninferiority trial; 4403 patients undergoing cardiac o

32 In a noninferiority trial, 499 patients with HCV genotype 2 o

33 In a noninferiority trial, 71.4% treated with lumbar decompre

34 In this randomized clinical noninferiority trial, a brief self-guided CBT interventi

35 In the noninferiority trial, a sustained response was reported

36 RAZOR was a phase 3 multicenter noninferiority trial across 15 academic medical centers

37 e conducted an open-label cluster-randomized noninferiority trial across 48 health centers in Cambodi

38 In this double-blind noninferiority trial, adult patients undergoing major ab

39 In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus

40 This dual-center, randomized, controlled, noninferiority trial aimed to prove that omission of dra

41 9 to April 2011, we included in a randomized noninferiority trial all HIV type 1-infected pregnant wo

42 IPANTS: Multicenter, randomized, open-label, noninferiority trial among 1150 adults at risk of aspira

43 iated, prospective, multicenter, randomized, noninferiority trial, an all-comers population requiring

44 12-week, single-blind, 3-group randomized noninferiority trial and subsequent 40-week maintenance

45 s regarding the design and interpretation of noninferiority trials and then explore some common metho

46 nferiority, features related to reporting of noninferiority trials, and the time trends.

47 local therapy trials, low-risk populations, noninferiority trials, and trials incorporating patient-

48 These trials have used the noninferiority trial approach.

49 Active-control noninferiority trials are being performed with increasin

50 Noninferiority trials are increasingly being performed.

51 The authors conclude that if noninferiority trials are to be applied to clinical and

52 d superiority trial designs are recommended; noninferiority trials are to be used sparingly given the

53 , AND PARTICIPANTS: This randomized clinical noninferiority trial assessed PTSD and depression at bas

54 We conducted this randomized, open-label, noninferiority trial at 14 centers in the United Kingdom

55 ed an international, open-label, randomized, noninferiority trial at 37 sites in Europe.

56 unblinded, monocentric, randomized clinical noninferiority trial at a tertiary neonatal intensive ca

57 ost designed primarily as placebo-controlled noninferiority trials, but with many also powered for su

58 ed, randomized, multicenter, single-blinded, noninferiority trial compared O-SES and N-BES in an all-

59 This double-blind, randomized, noninferiority trial compared the efficacy of intramuscu

60 andomized, multicenter, single-blind, 2-arm, noninferiority trial-compared 2 biodegradable polymer dr

61 ted BBS enrolled in a multicenter randomized noninferiority trial comparing 12-month treatment with M

62 We conducted an open-label, randomized noninferiority trial comparing 3 months of directly obse

63 ated, single-blind, multicentre, randomized, noninferiority trial comparing BP-SES versus DP-EES.

64 pragmatic, two-group, randomized, controlled noninferiority trial comparing collagenase injection wit

65 We performed a blinded, randomized, noninferiority trial comparing iodine povacrylex-alcohol

66 n (PRAGUE-17) was a multicenter, randomized, noninferiority trial comparing LAAC with DOACs.

67 he United Kingdom, we conducted a randomized noninferiority trial comparing low-dose and high-dose ra

68 conducted a 24-week randomized, open-label, noninferiority trial comparing oral mycophenolate mofeti

69 PRAGUE-17 was a randomized noninferiority trial comparing percutaneous LAAC (Watchm

70 PRAGUE-17 was a randomized noninferiority trial comparing percutaneous LAAC (Watchm

71 We conducted a multicenter, randomized, noninferiority trial comparing radical hysterectomy with

72 e, multicenter, single-blind, 1:1 randomized noninferiority trial comparing the BP-SES with control i

73 conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety o

74 multicenter, single-blind, all-comer, 2-arm, noninferiority trial comparing the everolimus-eluting st

75 We conducted an open-label, randomized, noninferiority trial comparing three-drug ART based on t

76 lobal clinical program was comprised of four noninferiority trials comparing vadadustat and darbepoet

77 rgeons Oncology Group Z0011 trial, a phase 3 noninferiority trial conducted at 115 sites and enrollin

78 TING AND PARTICIPANTS: A randomized clinical noninferiority trial conducted at 2 specialist child and

79 TS: This economic evaluation of a randomized noninferiority trial conducted at 2 specialist obsessive

80 is was a pragmatic, multicenter, randomized, noninferiority trial conducted at 22 pediatric intensive

81 In this randomized noninferiority trial conducted at 38 sites in Germany, w

82 In a multicenter, open label, randomized, noninferiority trial conducted at 49 sites in France, we

83 Randomized 2-arm noninferiority trial conducted at an academic medical ce

84 Randomized, open-label noninferiority trial conducted at Rahima Moosa Mother an

85 an ongoing single-blind, cluster randomized, noninferiority trial conducted between February 1, 2019,

86 Randomized, single-blind noninferiority trial conducted between the months of Oct

87 DISCOVER was a noninferiority trial conducted from 2016 to 2017.

88 Randomized, placebo-controlled, multicenter noninferiority trial conducted from August 2013 to Augus

89 OPTIMISE) study was a randomized, unblinded, noninferiority trial conducted in 69 primary care sites

90 ulticenter, open-label, randomized, phase 3, noninferiority trial conducted in 9 maternity hospitals

91 In this phase 3 randomized, controlled, noninferiority trial conducted in five African countries

92 In this noninferiority trial conducted in Germany, patients with

93 This is a phase 3, randomized, open-label, noninferiority trial conducted in patients with WHO cate

94 This is a phase 3, randomized, open-label, noninferiority trial conducted in patients with World He

95 Because testing for futility in this noninferiority trial corresponds to testing the hypothes

96 The outcome and interpretation of noninferiority trials depend on the magnitude of the non

97 The noninferiority trial design and recent infectious diseas

98 We used a noninferiority trial design with a noninferiority margin

99 s for systemic adjuvant treatment, including noninferiority trial design, choice of end points, and p

100 point was time to recurrence, tested using a noninferiority trial design.

101 romycin therapy as the comparator regimen in noninferiority trials designed to seek an indication for

102 Evidence is significantly limited by noninferiority trial designs and exclusion of critically

103 ed to growing use of composite endpoints and noninferiority trial designs in transplantation.

104 In this double-masked, randomized controlled noninferiority trial, eligible WLHIV were ages 18-40, no

105 placebo-controlled noninferiority trial enrolled 282 men from 27 centers in

106 This open-label, noninferiority trial enrolled 768 participants across 31

107 Randomized, double-blind, noninferiority trial enrolling 232 adults with recurrent

108 TS: Multicenter, randomized, 2 x 2 factorial noninferiority trial enrolling 824 children, aged 6 mont

109 ulticenter, placebo-controlled, double-blind noninferiority trial enrolling 8910 overweight or obese

110 G, AND PARTICIPANTS: Prospective, randomized noninferiority trial enrolling 995 women aged 40 years o

111 Phase III noninferiority trial examining efficacy and safety of co

112 We performed a phase 2 noninferiority trial examining the early fungicidal acti

113 Among the 327 noninferiority trials first posted between 2022 and 2023

114 electronic patient-level data from 9 phase 3 noninferiority trials for cIAI submitted to the US Food

115 Traditionally, noninferiority trials have required very large sample si

116 We performed a randomized noninferiority trial in 17 Dutch hospitals.

117 RTICIPANTS: A cluster-randomized, crossover, noninferiority trial in 18 emergency departments (EDs) i

118 avidae who participated in the ISTp arm of a noninferiority trial in 4 West African countries were sc

119 We conducted a noninferiority trial in 500 healthy adults comparing the

120 We conducted a cluster-randomized noninferiority trial in 63 internal-medicine residency p

121 This was a randomized (1:1) controlled noninferiority trial in 9 primary care centers in Tanzan

122 PARTICIPANTS: Randomized, active, controlled noninferiority trial in an urban setting, including pati

123 EAD is a phase 3, multicenter, double-blind, noninferiority trial in antiretroviral treatment-naive a

124 open-label, multicenter, randomized, phase 3 noninferiority trial in Cameroon.

125 We conducted a randomized, controlled noninferiority trial in Cuba.

126 ethods We conducted a multicenter randomized noninferiority trial in intermediate-risk prostate cance

127 cted a double-blind, randomized, controlled, noninferiority trial in Lilongwe, Malawi, to determine w

128 ization, therefore we conducted a randomized noninferiority trial in low immunologic risk renal trans

129 We conducted a pragmatic, open-label, noninferiority trial in New Zealand in which 1310 adult

130 We conducted a phase 3 noninferiority trial in participants with rifampin-resis

131 In this randomized noninferiority trial in Switzerland, we randomly assigne

132 In this double-blind, randomized, noninferiority trial in Uganda and Kenya, we assigned ad

133 We conducted a randomized, noninferiority trial in which adult candidates for heart

134 We conducted a randomized, controlled noninferiority trial in which filtered sunlight was comp

135 7T was a phase III, open-label, multicenter, noninferiority trial in which patients with advanced/met

136 We conducted a noninferiority trial in which patients with an indicatio

137 We conducted a noninferiority trial in which patients with clinically n

138 active-comparator-controlled, double-blind, noninferiority trial in which patients with type 2 diabe

139 We performed a randomized noninferiority trial in which TAVR with a self-expanding

140 We conducted a 48-week, double-blind, noninferiority trial in which we randomly assigned 353 p

141 Noninferiority trials in highest-impact journals commonl

142 This randomized noninferiority trial, in which participants were unaware

143 group analysis of a multicenter, randomized, noninferiority trial included 758 patients with de novo

144 This observer-blind, phase 3, noninferiority trial included adults aged 50-59 years, s

145 multicenter, open-label, randomized clinical noninferiority trial including patients with symptomatic

146 the methodology and reporting of antibiotic noninferiority trials including justification of noninfe

147 Publication of noninferiority trials increased over time (P<0.001).

148 d a national, cluster-randomized, pragmatic, noninferiority trial involving 117 general surgery resid

149 TING, AND PATIENTS: Prospective, randomized, noninferiority trial involving 250 patients with unilate

150 is of a randomized, multicenter, open-label, noninferiority trial involving 4447 patients with type 2

151 In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acu

152 Double-blind, randomized, crossover noninferiority trial involving 501 adults with at least

153 In a multicenter, randomized, noninferiority trial involving 689 otherwise healthy new

154 In a single-center, double-blind, noninferiority trial involving adults with unipolar depr

155 We conducted an open-label noninferiority trial involving children 9.0 to 11.9 mont

156 double-blind, randomized, placebo-controlled noninferiority trial involving children at primary healt

157 nducted an open-label, treatment-shortening, noninferiority trial involving children with nonsevere,

158 We conducted a phase 3, noninferiority trial involving healthy 2-to-29-year-olds

159 We performed a multicenter, randomized, noninferiority trial involving newborn infants (<24 hour

160 We conducted an open-label, randomized, noninferiority trial involving patients referred to ECT

161 ed an international, open-label, randomized, noninferiority trial involving patients who were receivi

162 This was a randomized, partially blinded, noninferiority trial involving patients with cancer with

163 In this multicenter, open-label, noninferiority trial involving patients with pulmonary s

164 Multicenter randomized, noninferiority trial involving patients with severe seps

165 We conducted an open-label, multicenter, noninferiority trial involving patients with symptomatic

166 We performed a randomized noninferiority trial involving women undergoing uterine

167 We performed a multicenter, randomized, noninferiority trial involving women with uncomplicated,

168 l of the resulting randomized trials--called noninferiority trials--is to establish that the novel tr

169 tort outcome interpretation, complexities of noninferiority trials, large sample sizes, and inadequat

170 rospective, 3-arm, double-masked, randomized noninferiority trial Lucentis, Eylea, Avastin in Vein Oc

171 This was a multicenter, open-label, noninferiority trial (margin 12%).

172 his was a secondary analysis of a randomized noninferiority trial (N=388) comparing conventional 10-H

173 Four Phase 3 noninferiority trials (n = 2433 participants) submitted

174 The primary outcome in this noninferiority trial (noninferiority margin of 8% that p

175 We designed a noninferiority trial (noninferiority margin, -10.5%) to

176 In this phase IIIb, multicenter, open-label, noninferiority trial, nonsurgical patients were randomiz

177 In noninferiority trials, novel oral anticoagulants (NOACs)

178 Randomized noninferiority trial of 290 children (aged 6-60 months),

179 Randomized, double-blind, placebo-controlled noninferiority trial of afebrile men with presumed sympt

180 G, AND PARTICIPANTS: This 12-week randomized noninferiority trial of behavioral therapy compared with

181 nter, international, open-label, randomized, noninferiority trial of biopsy-naive men from 20 centers

182 Thus, we conducted a noninferiority trial of cisplatin and paclitaxel versus

183 Thus, we conducted a noninferiority trial of cisplatin and paclitaxel versus

184 mes of different enrollment strategies for a noninferiority trial of LTBI treatment.Methods: We mathe

185 We performed a randomized noninferiority trial of patients undergoing elective col

186 was a pragmatic, patient- and rater-blinded, noninferiority trial of patients with major depression (

187 We conducted a population-based noninferiority trial of prostate cancer screening in whi

188 ter, randomized, double-blind, double-dummy, noninferiority trial of rituximab (375 mg per square met

189 We analyzed data from a noninferiority trial of short-course antimicrobial thera

190 G, AND PARTICIPANTS: Randomized, nonblinded, noninferiority trial of stepped vs early palliative care

191 We conducted a randomized, noninferiority trial of stopping versus continuing daily

192 CaRdial glucOse SuppresSion) is a crossover, noninferiority trial of the KD (endogenous ketosis) vers

193 h fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidias

194 R 1 and DISCOVER 2 were identically designed noninferiority trials of dalbavancin for the treatment o

195 he Update Committee reviewed three phase III noninferiority trials of dosing intervals, one systemati

196 enrolled based on positive TST.Conclusions: Noninferiority trials of LTBI should enroll based on the

197 ently updated guidelines for active control, noninferiority trials of selected severe infections caus

198 Rationale: Noninferiority trials of treatment for latent tuberculos

199 Noninferiority trials often require a long follow-up per

200 r than 90% the best that can be hoped for is noninferiority trial outcomes compared with current stan

201 In this phase III noninferiority trial, patients were randomly assigned to

202 In a noninferiority trial, patients with genotype 2 or 3 infe

203 torial, open-label, randomized, multicenter, noninferiority trial, patients with symptomatic aortic s

204 In this multicenter, international, noninferiority trial, patients with three-vessel coronar

205 In this nonrandomized, noninferiority trial, pediatric patients with standard-r

206 ETTING, AND PARTICIPANTS: In this randomized noninferiority trial, people who had a vaginal or cesare

207 In an investigator-initiated, randomized, noninferiority trial (prespecified margin 1.5 mm Hg), 32

208 We identified cardiovascular noninferiority trials published in JAMA, Lancet, or New

209 Stage 2 included all noninferiority trials registered between January 1, 2022

210 This noninferiority trial showed no more chronic sleep loss o

211 international randomized open-label phase 3 noninferiority trial showed that a 4-month daily regimen

212 Results of this randomized noninferiority trial suggest that behavioral therapy is

213 Accessible (MAGENTA) was a 4-arm, randomized noninferiority trial testing the effects of individualiz

214 ogy Group AAML1331 study is a nonrandomized, noninferiority trial that examined survival outcomes amo

215 onducted a phase 3, open-label, multicenter, noninferiority trial that included 1271 patients between

216 ds This was a randomized, partially blinded, noninferiority trial that involved survivors of breast c

217 margin is a key methodological parameter in noninferiority trials that affects both sample size calc

218 In a noninferiority trial, the efficacies of 10 days and 15 d

219 As a noninferiority trial, the primary analysis used the per-

220 paper tackles related controversial issues: noninferiority trials, the value of factorial designs, t

221 On the basis of noninferiority trials, tigecycline received Food and Dru

222 spective Randomized Multicenter Single-Blind Noninferiority Trial to Assess the Safety and Performanc

223 ormed an open-label, randomized, controlled, noninferiority trial to compare 6 weeks with 12 weeks of

224 ed a randomized, double-blind, double-dummy, noninferiority trial to compare long-acting injectable c

225 We performed a single-blinded noninferiority trial to compare perioperative hemodynami

226 We performed a multicenter, randomized, noninferiority trial to compare prophylaxis with ciprofl

227 national, open-label, randomized, controlled noninferiority trial to compare standard therapy for tre

228 We conducted a noninferiority trial to compare the outcomes of PCI perf

229 ousema and colleagues performed a randomized noninferiority trial to determine rates of unforeseen no

230 onducted a large, randomized, multinational, noninferiority trial to determine whether similar effica

231 lind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety

232 se 2-3, multicenter, randomized, controlled, noninferiority trial to evaluate the efficacy and safety

233 gainst Pneumonia (LEAP 1) study was a global noninferiority trial to evaluate the efficacy and safety

234 We conducted a randomized, controlled, noninferiority trial to investigate if intravenous, mult

235 scent girls in Vietnam who participated in a noninferiority trial to investigate whether immune respo

236 The study was designed as a noninferiority trial to show that the difference between

237 of active-control equivalence (also known as noninferiority) trials to establish efficacy of new ther

238 Most noninferiority trials used absolute rather than relative

239 This noninferiority trial was conducted among polio vaccine-n

240 tiated, prospective, randomized, open-label, noninferiority trial was conducted at 2 Austrian heart c

241 en-label, multicenter, randomized controlled noninferiority trial was conducted at 6 Kenyan hospitals

242 PANTS: This single-blind randomized clinical noninferiority trial was conducted at Karolinska Institu

243 The original noninferiority trial was conducted at the University of

244 andomized controlled, unblinded, prospective noninferiority trial was conducted between December 2017

245 , SETTING, AND PARTICIPANTS: This randomized noninferiority trial was conducted from May 2018 to May

246 A multicenter, randomized, open-label, noninferiority trial was conducted in 3 Spanish tertiary

247 A single-blind cluster-randomized controlled noninferiority trial was conducted in rural Rawalpindi,

248 In this multicenter, randomized, noninferiority trial, we assigned 303 very preterm infan

249 this international, multicenter, randomized, noninferiority trial, we assigned 564 preterm infants (g

250 In this international, noninferiority trial, we assigned adult patients with po

251 initiated, single-center, cluster-randomized noninferiority trial, we assigned patients undergoing di

252 his multicenter, randomized, parallel-group, noninferiority trial, we assigned patients with an inter

253 In this randomized, single-blind, noninferiority trial, we assigned patients with drug-ref

254 In a multicenter, randomized, controlled, noninferiority trial, we assigned persons who had early

255 prespecified kidney substudy of a randomized noninferiority trial, we compared a restrictive threshol

256 ter, randomized, double-blind, double-dummy, noninferiority trial, we compared rituximab (375 mg per

257 andomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 year

258 ndomized, double-blinded, active-controlled, noninferiority trial, we enrolled adults who were virolo

259 In this pragmatic, multicenter, randomized, noninferiority trial, we enrolled patients 18 years of a

260 In a randomized multicenter noninferiority trial, we enrolled patients with paroxysm

261 In this prospective, randomized, noninferiority trial, we investigated the omission of ax

262 In this double-blind, randomized, noninferiority trial, we prospectively evaluated the eff

263 In this double-blind noninferiority trial, we randomly assigned 307 patients

264 In this open-label, noninferiority trial, we randomly assigned 440 HIV-infec

265 In this multicenter, open-label, noninferiority trial, we randomly assigned 5243 adults u

266 In this pragmatic, international, noninferiority trial, we randomly assigned 8880 adult pa

267 l, parallel-group, randomized, double-blind, noninferiority trial, we randomly assigned adult patient

268 In a multicenter, noninferiority trial, we randomly assigned hospitalized

269 In this multicenter, noninferiority trial, we randomly assigned infants with

270 In this adaptive, open-label, noninferiority trial, we randomly assigned participants

271 In a two-by-two factorial, open-label, noninferiority trial, we randomly assigned patients for

272 In this multicenter, open-label, noninferiority trial, we randomly assigned patients who

273 In a multicenter, randomized, controlled, noninferiority trial, we randomly assigned patients with

274 In a multicenter, randomized, open-label, noninferiority trial, we randomly assigned patients with

275 In this open-label, noninferiority trial, we randomly assigned patients with

276 lticenter, double-blind, placebo-controlled, noninferiority trial, we randomly assigned pregnant wome

277 In this multicenter, open-label, controlled, noninferiority trial, we randomly assigned symptomatic p

278 In this open-label, multicenter, noninferiority trial, we recruited patients 14 to 50 yea

279 , randomized, open-label, active-controlled, noninferiority trials, we compared vadadustat with the e

280 er, randomized, double-blind, parallel-group noninferiority trial, which enrolled patients between Au

281 llel-group, double-blind, active-controlled, noninferiority trial with 4056 volunteers, demonstrating

282 SWiTCH was a noninferiority trial with a composite primary end point,

283 The trial was designed as a noninferiority trial with a noninferiority margin of 2.1

284 The study design was a double-blind, noninferiority trial with a prespecified noninferiority

285 domized, investigator-initiated, open-label, noninferiority trial with blinded central outcome adjudi

286 We conducted a randomized, double-blind, noninferiority trial with blinded central outcome adjudi

287 andomized, controlled, open-label, adaptive, noninferiority trial with blinded primary end point eval

288 PARTICIPANTS: This was a 2-period crossover, noninferiority trial with initial randomization to elect

289 multicentre, randomized, 2-arm, open-label, noninferiority trial with minimal exclusion criteria.

290 ed, open-label, adjudicator-blinded, phase 2 noninferiority trial with observer blinding for osocimab

291 The study was designed as noninferiority trial with progression-free survival (PFS

292 andomized, multicenter, single-blind, 2-arm, noninferiority trial with registry-based follow-up.

293 D PARTICIPANTS: Cluster randomized crossover noninferiority trial, with attending physicians as the u

294 Randomized, double-blind, active-controlled, noninferiority trial, with participant screening from No

295 ) was a multicenter, randomized, open-label, noninferiority trial, with participants randomized to HM